Keynote Speakers

Hover over speaker photo to view profile

Thursday, March 31, 2022 - 1300 - 1330hrs

Thursday, March 31, 2022 - 1300 - 1330hrs

Yuman Fong MD; USA
KN01 - Palliative Liver Resection
 
Yuman Fong MD

Dr. Yuman Fong is a graduate of Brown University (BA, Medieval Literature, 1981) and Cornell University Medical College (MD, 1984). He is the Sangiacomo Chair and Chairman of the Department of Surgery at the City of Hope Medical Center.

Dr. Fong is best known clinically for his extensive work in the field of liver and pancreatic surgery––especially for pioneering many laparoscopic, robotic and ablative therapies for these cancers. He has assisted in the design and deployment of many novel surgical tools.

Dr. Fong has also been active in biologic bench investigation.  His early research was in immune activation during cancer or infection.  He was part of the group that discovered tumor necrosis factor and helped established the field of innate immunity. His laboratory focus over the last 15 years has been in the field of gene therapy, designing and studying the use of genetically modified viruses for the killing of cancer. His group was the first to administer recombinant viruses into the blood stream of man as a cancer treatment. His leadership in this field on the national level has included serving as the Chair of the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health.

He has co-authored over 700 peer reviewed articles and 12 text books. He has served on the editorial boards of 14 journals, and is currently Editor-in-Chief of Molecular Therapy Oncolytics (Cell Press).

Julie Heimbach MD; USA
KN02 - Contemporary Management of Hilar Cholangiocarcinoma
Julie Heimbach MD

Julie Heimbach is a Professor of Surgery and the Chair of Division of Transplantation at the Mayo Clinic College of Medicine in Rochester, MN.  She has dedicated a significant amount of time to UNOS, having served on numerous committees as well as the Board of Directors, and most recently, as the chair of the liver-Intestine committee.   Dr. Heimbach also recently served on the ASTS council and currently serves as an Associate Editor both for the American Journal of Transplantation, and for the Journal of Hepatology.  Her clinical and research interests include liver transplantation for hepatobiliary malignancies, living donor transplantation, and obesity in liver transplantation.

Andrea Schlegel MD; Italy/Switzerland
KN03 - An Ideal Liver Graft
Machine Perfusion
Andrea Schlegel MD

Andrea Schlegel is a certified Transplant and Hepatobiliary Surgeon, currently working at the Careggi University Hospital in Florence, Italy and the University Hospital in Zurich, Switzerland.

Andrea Schlegel grew up in Dresden, Germany, where she attended the Justus-von-Liebig University in Giessen, Germany, subsequently graduating in Medicine in 2007. She received her surgical training at University Hospital in Zurich, Switzerland, including a three-year postdoctoral research fellowship and completing her Chief Residency in 2015. She then moved to England to complete a fellowship in Hepatobiliary Surgery and Liver Transplantation at the Queen Elizabeth Hospital in Birmingham, where she then worked as a Consultant Surgeon, before returning to the Division of Abdominal Surgery and Transplantation at the University of Zurich. In 2020, she was recruited to build and support the translational research at the Careggi University Hospital in Florence, Italy with a focus on a comparative analyses of various machine perfusion techniques in transplantation of solid organs.

Since more than 10 years, her research focus on underlying mechanisms of ischemia/reperfusion injury and protective effects of machine perfusion technology. One of Dr. Schlegel`s main interest is the development of new markers to predict organ viability during perfusion, to enable the safe use of high-risk livers. One main topic her group focus on is the comparison of the mitochondrial metabolism in marginal livers during machine perfusion and transplantation.

Dr. Schlegel's clinical interests include liver transplantation and hepatobiliary surgery. Based on her work in Switzerland, England and Italy, she has developed significant clinical experience with the transplantation of risky livers and has developed new prediction models to improve outcomes based on improved donor-recipient matching. She is a co-author of over 120 journal articles and book chapters.

Thursday, March 31, 2022 - 1300 - 1330hrs

Thursday, March 31, 2022 - 1300 - 1330hrs

Yuman Fong MD; USA
KN01 - Palliative Liver Resection
 
Yuman Fong MD

Dr. Yuman Fong is a graduate of Brown University (BA, Medieval Literature, 1981) and Cornell University Medical College (MD, 1984). He is the Sangiacomo Chair and Chairman of the Department of Surgery at the City of Hope Medical Center.

Dr. Fong is best known clinically for his extensive work in the field of liver and pancreatic surgery––especially for pioneering many laparoscopic, robotic and ablative therapies for these cancers. He has assisted in the design and deployment of many novel surgical tools.

Dr. Fong has also been active in biologic bench investigation.  His early research was in immune activation during cancer or infection.  He was part of the group that discovered tumor necrosis factor and helped established the field of innate immunity. His laboratory focus over the last 15 years has been in the field of gene therapy, designing and studying the use of genetically modified viruses for the killing of cancer. His group was the first to administer recombinant viruses into the blood stream of man as a cancer treatment. His leadership in this field on the national level has included serving as the Chair of the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health.

He has co-authored over 700 peer reviewed articles and 12 text books. He has served on the editorial boards of 14 journals, and is currently Editor-in-Chief of Molecular Therapy Oncolytics (Cell Press).

Julie Heimbach MD; USA
KN02 - Contemporary Management of Hilar Cholangiocarcinoma
Julie Heimbach MD

Julie Heimbach is a Professor of Surgery and the Chair of Division of Transplantation at the Mayo Clinic College of Medicine in Rochester, MN.  She has dedicated a significant amount of time to UNOS, having served on numerous committees as well as the Board of Directors, and most recently, as the chair of the liver-Intestine committee.   Dr. Heimbach also recently served on the ASTS council and currently serves as an Associate Editor both for the American Journal of Transplantation, and for the Journal of Hepatology.  Her clinical and research interests include liver transplantation for hepatobiliary malignancies, living donor transplantation, and obesity in liver transplantation.

Andrea Schlegel MD; Italy/Switzerland
KN03 - An Ideal Liver Graft
Machine Perfusion
Andrea Schlegel MD

Dr. Yuman Fong is a graduate of Brown University (BA, Medieval Literature, 1981) and Cornell University Medical College (MD, 1984). He is the Sangiacomo Chair and Chairman of the Department of Surgery at the City of Hope Medical Center.

Dr. Fong is best known clinically for his extensive work in the field of liver and pancreatic surgery––especially for pioneering many laparoscopic, robotic and ablative therapies for these cancers. He has assisted in the design and deployment of many novel surgical tools.

Dr. Fong has also been active in biologic bench investigation.  His early research was in immune activation during cancer or infection.  He was part of the group that discovered tumor necrosis factor and helped established the field of innate immunity. His laboratory focus over the last 15 years has been in the field of gene therapy, designing and studying the use of genetically modified viruses for the killing of cancer. His group was the first to administer recombinant viruses into the blood stream of man as a cancer treatment. His leadership in this field on the national level has included serving as the Chair of the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health.

He has co-authored over 700 peer reviewed articles and 12 text books. He has served on the editorial boards of 14 journals, and is currently Editor-in-Chief of Molecular Therapy Oncolytics (Cell Press).

Thursday, March 31, 2022 - 1300 - 1330hrs

Thursday, March 31, 2022 - 1300 - 1330hrs

Yuman Fong MD; USA
KN01 - Palliative Liver Resection
 
Yuman Fong MD

Dr. Yuman Fong is a graduate of Brown University (BA, Medieval Literature, 1981) and Cornell University Medical College (MD, 1984). He is the Sangiacomo Chair and Chairman of the Department of Surgery at the City of Hope Medical Center.

Dr. Fong is best known clinically for his extensive work in the field of liver and pancreatic surgery––especially for pioneering many laparoscopic, robotic and ablative therapies for these cancers. He has assisted in the design and deployment of many novel surgical tools.

Dr. Fong has also been active in biologic bench investigation.  His early research was in immune activation during cancer or infection.  He was part of the group that discovered tumor necrosis factor and helped established the field of innate immunity. His laboratory focus over the last 15 years has been in the field of gene therapy, designing and studying the use of genetically modified viruses for the killing of cancer. His group was the first to administer recombinant viruses into the blood stream of man as a cancer treatment. His leadership in this field on the national level has included serving as the Chair of the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health.

He has co-authored over 700 peer reviewed articles and 12 text books. He has served on the editorial boards of 14 journals, and is currently Editor-in-Chief of Molecular Therapy Oncolytics (Cell Press).

Julie Heimbach MD; USA
KN02 - Contemporary Management of Hilar Cholangiocarcinoma
Julie Heimbach MD

Julie Heimbach is a Professor of Surgery and the Chair of Division of Transplantation at the Mayo Clinic College of Medicine in Rochester, MN.  She has dedicated a significant amount of time to UNOS, having served on numerous committees as well as the Board of Directors, and most recently, as the chair of the liver-Intestine committee.   Dr. Heimbach also recently served on the ASTS council and currently serves as an Associate Editor both for the American Journal of Transplantation, and for the Journal of Hepatology.  Her clinical and research interests include liver transplantation for hepatobiliary malignancies, living donor transplantation, and obesity in liver transplantation.

Andrea Schlegel MD; Italy/Switzerland
KN03 - An Ideal Liver Graft
Machine Perfusion
Andrea Schlegel MD

Dr. Yuman Fong is a graduate of Brown University (BA, Medieval Literature, 1981) and Cornell University Medical College (MD, 1984). He is the Sangiacomo Chair and Chairman of the Department of Surgery at the City of Hope Medical Center.

Dr. Fong is best known clinically for his extensive work in the field of liver and pancreatic surgery––especially for pioneering many laparoscopic, robotic and ablative therapies for these cancers. He has assisted in the design and deployment of many novel surgical tools.

Dr. Fong has also been active in biologic bench investigation.  His early research was in immune activation during cancer or infection.  He was part of the group that discovered tumor necrosis factor and helped established the field of innate immunity. His laboratory focus over the last 15 years has been in the field of gene therapy, designing and studying the use of genetically modified viruses for the killing of cancer. His group was the first to administer recombinant viruses into the blood stream of man as a cancer treatment. His leadership in this field on the national level has included serving as the Chair of the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health.

He has co-authored over 700 peer reviewed articles and 12 text books. He has served on the editorial boards of 14 journals, and is currently Editor-in-Chief of Molecular Therapy Oncolytics (Cell Press).

Thursday, March 31, 2022 - 1300 - 1330hrs

Friday, April 1, 2022 -1300 - 1330hrs

Claudio Bassi MD; Italy
KN04 - IPMN Treatment Guidelines Update
Claudio Bassi MD

Claudio Bassi, graduated in Medicine in 1977 at Padua University and in the same year he won a scholarship in General Surgery. In 1985 he was appointed Assistant-Professor and in 2004 as Associate Professor and since 2005 as Full Professor at the Surgical Department in Verona, where he actually works as Chairman of the General Surgery and of the Verona Pancreas Institute. He specialized in General Surgery and Thorax Surgery. His research is mainly concerned with the physiopathology and surgical therapy of pancreopaties. (HI (89). He discussed his results at many Italian and International Congresses. He is an active fellow of the Italian Society of Surgery, Italian Pancreatic Association, European Pancreatic Club, International Association of Pancreatology, Pancreas Club, European Digestive Surgery, European Surgical Association and International Hepato-Pancreatic-Biliary Association. He works as a Member of the IAP and IHPB Councils and in the Editorial Board of several international journals. He published sever papers in impacted international journal, mainly about Surgery and Gastroenterology, dealing with particular attention to the infections relate to Acute Pancreatitis and Pancreatic Tumors.

Jin-Young Jang MD; Korea
KN05 - Management of
Choledochal Cysts
Jin-Young Jang MD

Professor Jin-Young Jang graduated from Seoul National University, and he continued his resident and fellowship training in biliary tract and pancreas surgery at Seoul National University Hospital (SNUH). He is currently the professor in the Department of Surgery at Seoul National University College of Medicine. He is one of world famous pancreas and biliary surgeon focusing on evidence based surgery. He has released over 450 SCI(E) scientific papers and is actively working as a member of many clinical guidelines and global studies for pancreas and biliary disease including IPMN, pancreatic cancer and GB cancer. He is an expert surgeon in minimally invasive surgery such as laparoscopic and robotic surgery. His center has performed over 300 robotic assisted PPPD and 700 advanced robotic biliary-pancreatic surgery.

Melinda Bachini; USA
KN06 - Quality of Care from a Patient's Perspective
Melinda Bachini

Melinda Bachini is a 12-year survivor of cholangiocarcinoma. In 2012 she was treated at the National Cancer Institute by Dr. Rosenberg with a clinical trial using Adoptive Cell Therapy with TIL. Due to her exceptional and breakthrough response to treatment, her story was published in the New York Times and other media. 

Melinda is married and the mother of six children, grandmother to one. She is passionate about patient advocacy. Her position as Director of Advocacy for the Cholangiocarcinoma Foundation allows Melinda to interact, support and educates others touched by this cancer. 

Melinda had previously volunteered for seven years with the Cholangiocarcinoma Foundation and in August of 2017 came on as staff. She also worked for over 15 years in the Emergency Medical Field as an EMT Paramedic.

Melinda serves as a patient advocate for the NCI Hepatobiliary Task Force, the NCI Patient Advocate Steering Committee (PASC), ECOG-ACRIN GI Committee, ECOG-ACRIN Cancer Research Advocacy Committee, NCI Council of Research Advocates, and the NCCN Hepatobiliary Guideline Panel.  She participated as a panelist in the Cancer Moonshot – Community Oncology Event at the White House. Melinda has served as a Consumer Reviewer for the Department of Defense for several years.

Thursday, March 31, 2022 - 1300 - 1330hrs

Saturday, April 2, 2022 - 1300 - 1330 hrs

Jennifer Tseng MD; USA
KN07 - Pancreatic Cancer Surgery: Evidence and Future
Jennifer Tseng MD

Dr. Jennifer F. Tseng was born in Berkeley and grew up in San Jose, California. She attended Stanford University, majoring in English and biological sciences, followed by medical school at the University of California, San Francisco. Dr. Tseng did her surgery residency at Massachusetts General Hospital, where she also served as staff surgeon (super-Chief), followed by a surgical oncology fellowship at the University of Texas MD Anderson Cancer Center. Dr. Tseng began her faculty career at the University of Massachusetts Medical Center in 2005; while there, she completed her master of public health degree at the Harvard T.H. Chan School of Public Health. Dr. Tseng was recruited to Beth Israel Deaconess Medical Center and Harvard Medical School as Chief of Surgical Oncology in 2011, where she rose to the rank of Professor of Surgery at Harvard. In 2017, she was appointed as the James Utley Professor and Chair of Surgery at Boston University and the Surgeon-in-Chief at Boston Medical Center.

Dr. Tseng is a surgical oncologist whose practice includes pancreas, hepatobiliary, and gastric surgery. She is also a health services researcher focusing on risk prediction and prevention, disparities in surgical and cancer care, and models to build health equity. Dr. Tseng founded Surgical Outcomes Analysis & Research (SOAR) in 2007. SOAR is now the hub of outcomes research for the Boston University School of Medicine/Boston Medical Center Department of Surgery. Dr. Tseng is the immediate past secretary of the Society for Surgery of the Alimentary Tract, is a founder and a past president of the Society of Asian Academic Surgeons, is on the executive councils of the Society of Surgical Oncology and the Society of University Surgeons, and is a councilor on the American Board of Surgery (ABS), where she will take over as chair of the ABS Research Committee in June 2021. She serves on a number of editorial boards and is a deputy editor for JAMA Surgery. Dr. Tseng has mentored multiple trainees to great success in national and international meetings,

funded grants, and peer-reviewed publications, and their achievements are her source of greatest pride. Dr. Tseng lives with her husband Dr. Marc Sabatine and their two teenage children, Matthew (“Matteo”) and Natalie, in greater Boston.

Masukazu Yamamoto MD; Japan
KN08 - Liver Resection in
Advanced HCC
Masukazu Yamamoto MD

Office: Utsunomiya Memorial Hospital, Tochigi, Japan

Specialty: Hepatobiliary pancreatic surgery

Education:

     4/76-3/81   Faculty of Medicine, Tsukuba University

     3/89          Degree of Medical Science (PhD), Tokyo Women’s Medical University

Positions and appointments:

    2006-2021; Professor and Chairman, Department of Surgery, Institute of Gastroenterology, Tokyo Women’s Medical University

2010-2021; Chairman, Institute of Gastroenterology, Tokyo Women’s Medical University

2021-present; Director. Utsunomiya Memorial Hospital

JSHPBS activities

2016-2020; President of Japanese Society Hepato-Pancreato- Biliary Surgery

IHPBA A-PHPBA activities

2015-2017; Congress president of A-PHPBA 2017, Yokohama, Japan

2017-2021; Chairman of the scientific committee of A-PHPBA